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Abstract
Introduction: Analyses of large clinical datasets from early arthritis cohorts permit the development of algorithms
that may be used for outcome prediction in individual patients. The value added by routine use of musculoskeletal
ultrasound (MSUS) in an early arthritis setting, as a component of such predictive algorithms, remains to be
determined.
Methods: The authors undertook a retrospective analysis of a large, true-to-life, observational inception cohort of
early arthritis patients in Newcastle upon Tyne, UK, which included patients with inflammatory arthralgia but no
clinically swollen joints. A pragmatic, 10-minute MSUS assessment protocol was developed, and applied to each of
these patients at baseline. Logistic regression was used to develop two “risk metrics” that predicted the
development of a persistent inflammatory arthritis (PIA), with or without the inclusion of MSUS parameters.
Results: A total of 379 enrolled patients were assigned definitive diagnoses after ≥12 months follow-up (median
28 months), of whom 162 (42%) developed a persistent inflammatory arthritis. A risk metric derived from 12
baseline clinical and serological parameters alone had an excellent discriminatory utility with respect to an
outcome of PIA (area under receiver operator characteristic (ROC) curve 0.91; 95% CI 0.88 to 0.94). The
discriminatory utility of a similar metric, which incorporated MSUS parameters, was not significantly superior (area
under ROC curve 0.91; 95% CI 0.89 to 0.94). Neither did this approach identify an added value of MSUS over the
use of routine clinical parameters in an algorithm for discriminating PIA patients whose outcome diagnosis was
rheumatoid arthritis (RA).
Conclusions: MSUS use as a routine component of assessment in an early arthritis clinic did not add substantial
discriminatory value to a risk metric for predicting PIA.
 
Introduction
National and international guidelines increasingly empha-
sise the importance of early diagnosis in the management
of new onset inflammatory arthritis and support the estab-
lishment of dedicated early arthritis (EA) clinics [1,2].
However, despite new classification criteria for rheumatoid
arthritis (RA) [3,4], a substantial proportion of EA clinic
attendees have un-classifiable disease, and are labelled as
having undifferentiated arthritis (UA) [5,6].
Analyses of large clinical datasets from early arthritis
cohorts permit the development of algorithms that may
be used for outcome prediction in individuals - an
approach which yielded a validated “prediction rule” for
use in UA patients, in which a range of baseline clinical
and laboratory parameters are weighted and combined
to yield a score that relates to RA progression risk [7-9].
It has been suggested that every bit as clinically impor-
tant as identifying individuals specifically destined for
RA is the more general goal of predicting persistent
inflammatory arthritis (PIA) amongst EA patients as a
whole [10-12]. Hence, a predictive tool applicable to all
EA clinic attendees, which distinguishes chronic
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inflammatory from non-inflammatory/self-limiting dis-
ease, could accelerate access to disease-modifying anti-
rheumatic drugs (DMARDs) for those most likely to
benefit from them. Musculoskeletal ultrasound has
shown promise as an evaluation tool in the setting of
early arthritis [13,14], but the value it adds to a thor-
ough clinical assessment, for example, as a component
of a predictive algorithm, remains to be quantified.
The Newcastle EA Clinic accepts patients clinically
suspected of having new-onset inflammatory arthritis by
their referring physician [15]. Blood test results and/or
the presence of clinically inflamed joints are not
required at the time of referral, ensuring inclusion of an
important group of patients with new-onset inflamma-
tory arthralgia into the resultant cohort. Such patients
typically describe joint pain with morning stiffness, but
have no clinically inflamed/swollen joints on examina-
tion. In this observational cohort study, we used the
principles adopted by van der Helm-van Mil et al. [16]
to construct a predictive algorithm for PIA amongst EA
clinic attendees. We then asked whether the addition of
the most predictive element(s) of a short, pragmatic
MSUS screening protocol improved its predictive utility.
Materials and methods
Subjects and data collection
Consenting patients ≥16 years of age and presenting
with new-onset arthralgia to the Newcastle EA clinic
between September 2006 and November 2009 were
included into the study. Detailed baseline demographic
and clinical parameters were recorded during the
patients’ first EA clinic visit by an experienced specialist
nurse, at which time routine blood tests included acute
phase markers and autoantibodies. A “joint pattern
score” (JPS) between 0 and 2.5 was also recorded for
each patient, reflecting the localisation and distribution
of symptomatic joints at presentation according to the
system described by van der Helm-van Mil et al. [16].
An initial diagnosis was assigned to each patient by
their consulting rheumatologist according to a “working
diagnosis proforma” (Table 1) [15]. RA was diagnosed
only where 1987 ACR classification criteria [17] were
fulfilled; UA was defined as a “suspected inflammatory
arthritis where RA remained a possibility, but where
established classification criteria for any rheumatological
condition remained unmet”. This initial diagnosis was
updated by the rheumatologist at each subsequent clinic
visit for the duration of the study, which was greater
than 12 months for all patients. A knowledge of out-
come diagnoses was used to further categorise patients
according to whether or not they developed a persistent
inflammatory arthritis (PIA versus non-PIA). Hence, RA,
psoriatic arthritis, enteropathic arthritis, ankylosing
spondylitis, undifferentiated spondyloarthropathy,
connective tissue disease and other inflammatory arthri-
tides constituted PIA outcomes. A subset of individuals
assigned the “self-limiting inflammatory/reactive arthri-
tis” outcome, who had definite reactive arthritis warrant-
ing DMARD treatment, were also included in the PIA
grouping. Remaining EA clinic attendees, diagnosed
with self-limiting inflammatory arthritis, crystal patholo-
gies, osteoarthritis or non-inflammatory arthralgia at fol-
low-up, formed the non-PIA category. Enrolled patients
consented to participate in the study, which received a
favourable review by the Newcastle and North Tyneside
Local Research Ethics Committee.
MSUS protocol
The same Aplio™ Diagnostic Ultrasound System
(Toshiba Medical Systems Corporation, Tochigi-Ken,
Japan) was employed for all MSUS assessments. This
employed a 12 MHz probe, the screening protocol used
in the study could be completed in approximately 10
minutes, and was performed in the EA clinic by one of
three experienced MSUS practitioners. A total of 16
peripheral small joints were routinely evaluated: the sec-
ond to fourth metacarpophalangeal (MCP) and proximal
interphalangeal (PIP) joints bilaterally (dorsal and volar
longitudinal planes, neutral and flexed position) and the
first and second metatarsophalangeal (MTP) joints bilat-
erally (dorsal longitudinal plane only). Semiquantitative
scores were assigned at each site for three “domains":
grey-scale synovitis, power Doppler signal and bony ero-
sion, according to consensus definitions [18,19]. For
Table 1 Categorisation of working diagnoses
• RA □
• UA □














Categorisation of working diagnoses used amongst early arthritis patients at
inception and follow-up during the course of this study. Consultant
rheumatologists were asked to tick one box at each clinic visit, indicating the
best description of their expert opinion of the diagnosis at a given time. See
text. *Where modified New York criteria for the diagnosis of ankylosing
spondylitis were not met, but the diagnosis was suspected in the context of
seronegative inflammatory disease, consultants were asked to record a
diagnosis of “undifferentiated spondyloarthritis”.
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each domain at each hand joint, only the higher of the
dorsal and volar scores was recorded. Each domain was
scored on a 0 to 3 semi-quantitative scale, based on the
system first suggested by Szudlarek et al. [20], but
adopting the modification of Scheel et al. in respect of
grey-scale synovitis, whereby effusion and synovial thick-
ening were grouped to give a single, combined score
[21]. In recognition that a degree of grey-scale synovitis
at MTP1 may be physiological [13], a semi-quantitative
score of 1 at this joint did not count towards the overall
score for this domain. Once complete MSUS datasets
had been obtained for 397 patients, five potentially use-
ful dichotomous variables were identified with respect
to diagnostic outcome. Broadly, these parameters repre-
sented either “synovitis load” within a defined number
of joints (for example, the sum of semi-quantitative
grey-scale synovitis scores of the 16 specified joints), or
“proportionate joint involvement” (for example, the pro-
portion of joints in which any power doppler signal was
present); optimal cut-off values for each parameter were
determined from the available datasets.
During preliminary work for the study, inter-observer
agreement between assessors was determined. For exam-
ple, 16 small hand/foot joints of 20 EA clinic patients (a
total of 316 joints) were independently scanned by two
practitioners (PNP and AGP), each being blinded to the
recorded findings of the other at the time of documen-
tation. Semi-quantitative scores of both grey-scale syno-
vitis and power Doppler synovitis were dichotomised
into the presence or absence of a score ≥1 for each
joint, and resultant Kappa statistics (0.56 for grey-scale
and 0.64 for power Doppler synovitis) demonstrated
moderately good inter-observer agreement, which is
comparable with that seen in other settings [22]. Com-
parable kappa statistics were obtained between other
practitioners using the same method. Further prelimin-
ary work confirmed an excellent intra-observer reliabil-
ity for small joint MSUS measurements. For example,
anonomysed images from 18 patients, scored by AGP
on separate occasions (two weeks apart) in random
sequence for the presence/absence of grey-scale and
power Doppler semi-quantitative scores ≥2, yielded
kappa values of 0.85 and 0.91, respectively.
Statistical analysis
Student’s t-tests and Mann-Whitney U tests (parametric
and non-parametric data, respectively), contingency
table statistics (kappa tests and Pearson’s chi-squared
test, including Yates’ continuity correction and effect
size calculations for 2 × 2 tables), logistic regression
analyses and the construction of receiver operator char-
acteristic (ROC) curves were carried out using SPSS ver-
sion 15 (SPSS Inc., Chicago, IL, USA).
For the primary logistic regression analyses of the
complete Early Arthritis Clinic (EAC) cohort, a back-
ward selection approach was used which rationally iden-
tified the most significant independent variables, with a
P-value of 0.1 having been set as the removal criterion.
Where variables were available in either continuous or
categorical formats the choice of whether to enter a
given variable in continuous or categorical format was
made based on an iterative process, whereby the accura-
cies of derived models for discriminating EA-PIA versus
EA-non-PIA were compared - only the derivation of the
final model is outlined here. In the resultant regression
models, the predicted probability of PIA was related to
the covariates via the following prognostic index: B1x1 +
B2x2+... ...+Bnxn, where × refers to a specific covariate, n
is the total number of covariates in the model, and the
regression coefficient (B) of each covariate indicates an
estimate of the relative magnitude of its prognostic
power. Using this prognostic index, it was possible to
calculate the predicted probability of PIA developing for
every EA patient. For ease of use, the values of regres-
sion coefficients (B) incorporated into the index were
doubled and then rounded to the nearest 0.5 to provide
a simplified prognostic index for clinical application,
without substantially altering the prognostic utility of
the tool. Where data were missing for individual sub-
jects (within the “minimum dataset” constraints outlined
above), median values from the final study cohort were
imputed to enable multivariate analysis of the complete
dataset. Variables requiring modification in this way
(number, percentage of individuals) were: C-reactive
protein (CRP) (5, 1%), erythrocyte sedimentation rate
(ESR) (9, 2%), anti-citrullinated peptide autoantibody
(ACPA) (9, 2%), and rheumatoid factor (RF) (3, 0.8%).
An entirely analogous approach was then used for the
derivation of regression models for predicting an RA
diagnostic outcome amongst the sub-cohort of patients
classified as having PIA, and for predicting RA amongst
those who presented with UA.
Results
EA patient cohort and univariate analysis of baseline
characteristics
A total of 389 eligible patients were recruited between
September 2006 and April 2009 inclusive, and were fol-
lowed up for a minimum of 12 months (median 27;
range 12 to 44 months); 10 had arthritis that remained
undifferentiated at the end of the follow-up period, and
were excluded from analysis. The diagnostic evolution
of the remaining 379 patients is presented in Table 2.
The baseline clinical and serological characteristics of
patients in whom PIA did or did not develop are com-
pared in Table 3, each of 12 variables being considered
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both categorically and continuously where possible;
these were: age, sex, smoking status, symptom duration,
tender joint count, swollen joint count, joint pattern
score, early morning stiffness (EMS), ESR, CRP, RF and
ACPA status. Five MSUS parameters for synovitis were
identified as having potential discriminatory utility at
baseline with respect to an outcome of PIA; namely, (i)
“sum of scores (grey-scale domain) for total of 16
scanned joints,” (ii) “sum of scores (grey-scale domain)
for 6 scanned joints of worst-affected hand,” (iii) “num-
ber out of 16 total scanned joints scoring ≥1 (grey-scale
domain)”, (iv) “sum of scores (power Doppler domain)
for total of 16 scanned joints” and (v) “number out of
16 total scanned joints scoring >1 (power Doppler
domain) (see also Methods). Findings in relation to
these parameters, as well as the presence/absence of
MSUS erosions were also compared (as dichotomous
variables, according to pre-determined optimal cut-offs)
between comparator groups (Table 3).
Predictive algorithm for PIA: no MSUS
The 12 clinical/serological variables were entered into a
backward stepwise logistic regression analysis, with PIA
versus non-PIA outcome as the dependent variable
(Table 4). Amongst 379 EA clinic patients, and after
sequential removal of non-significant parameters, 7 vari-
ables were independently associated with PIA. The final
model containing these predictors was significantly asso-
ciated with PIA (c2 (7 degrees of freedom) = 240.4; P <
0.001), and explained between 47% (Cox and Snell R
square) and 63% (Nargelkerke R squared) of the var-
iance in diagnostic outcome [23]. A simple “risk metric”
for clinical use could be calculated for each of the 379
individuals in the EA cohort, based in each case on the
values of the seven independent predictive variables in
the regression model [16] (Figure 1 and see also
Methods). This risk metric was shown to have an excel-
lent discriminatory ability in the current dataset through
the construction of a ROC curve, the area under which
was 0.91 (standard error of mean (SEM) = 0.015, P <
0.001; Figure 2).
The incidence of PIA in our cohort was 162/379, or
0.42. Taking this to represent the prior probability of
PIA amongst our EA cohort, and employing a single
cut-off value for the prediction score, the positive and
negative predictive values (PPV and NPV) of a score
≥4.0 were 0.83 in both cases (95% CIs 0.75 to 0.88 and
0.78 to 0.88, respectively), the positive and negative like-
lihood ratios (+LR and -LR) being 6.4 (4.41 to 9.25) and
0.27 (0.20 to 0.35), respectively. In the absence of exter-
nal, independent validation, studies which rely on statis-
tical modelling by logistic regression may lead to over-
optimistic assessment of predictive utilities due to the
phenomenon of “over-fitting” [23]. By employing a strin-
gent 10-fold random sub-sampling cross-validation to
account for this possibility [24], our model’s PPV with
respect to PIA reduced to 0.72 (0.68 to 0.76), but the
NPV was maintained at 0.85 (0.83 to 0.88) (+LR and
-LR corrected to 3.56 (3.10 to 4.08) and 0.22 (0.18 to
0.26), respectively).
Predictive algorithm for PIA is not improved by
incorporation of MSUS parameter(s)
Backward stepwise logistic regression analysis was
repeated, with the addition of the five discriminatory
MSUS parameters as independent variables alongside
the seven clinical/serological variables previously identi-
fied (and listed in Table 4). The results of this revised
multivariate analysis are presented in Table 5, which
identifies a predictive model very similar to that pre-
viously derived, comprising seven independent predic-
tors of PIA, but with “joint pattern score” being
Table 2 Diagnostic evolution of EA patients
Working diagnostic category (consulting rheumatologist’s opinion). Number (%) assigned diagnosis (total = 379)
Inception: Close of follow-up: (median 28 months)
Undifferentiated arthritis 91 (24.0) 0 (-)
Rheumatoid arthritis 69 (18.2) 102 (26.9)
Psoriatic arthritis 24 (6.3) 25 (6.6)
Enteropathic arthritis 3 (0.8) 4 (1.1)
Reactive/self-limiting inflammatory arthritis 21 (5.5) 36 (9.5)
Ankylosing spondylitis 0 ( - ) 2 (0.5)
Undifferentiated spondyloarthritis 7 (1.8) 9 (2.4)
Crystal arthritis (gout/pyrophosphate) 17 (4.5) 17 (4.5)
Connective tissue disease 5 (1.3) 7 (1.8)
Other inflammatory arthropathy 7 (1.8) 9 (2.4)
Osteoarthritis 66 (17.4) 78 (20.6)
Other non-inflammatory/arthralgia 69 (18.2) 90 (23.6)
Breakdown of inception and outcome diagnoses for 379 EA clinic patients.
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Table 3 Univariate analysis of baseline clinical and MSUS parameters









-cat; >50 (%) 51 49 51 0.533
-cont; mean (SD) 50.9 (36 to 66.) 48.5 (34.5 to 62.5) 53.8 (37.8 to 69.8) 0.057
Sex; F (%) 69 71 67 0.540
Ever smoked? (%) 54.1 100, 117 74, 88 0.999
Sx durn (weeks)
-cat; ≥20 (%) 51 61 38 <0.001
-cont; median (IQR) 20 (10 to 34) 24 (12 to 52) 12 (8 to 24) <0.001
TJC /72
-cat; >6 (%) 51 48 54 0.299
-cont; median (IQR) 7 (2 to 14) 6 (2 to 14) 7.5 (3 to 15) 0.052
SJC /72
-cat; ≥1 (%) 46 26 73 <0.001
-cont; median (IQR) 0 (0 to 3) 0 (0 to 1) 2 (0 to 6) <0.001
JPS
-cat; ≥2 (%) 66 56 78 <0.001
-cont; median (IQR) 2 (1.5 to 2) 2 (1.5 to 2) 2 (2 to 2.5) <0.001
EMS (hours)
-cat; ≥1 (%) 50 39 65 <0.001
-cont; median (IQR) 1 (0.2 to 2) 0.5 (0.05 to 1.5) 1 (0.5 to 2) <0.001
CRP (g/l)
-cat; <5,5 to 14,≥14 (%) 49,26,25 66, 23, 11 25, 30, 45 <0.001
-cont; median (IQR) 5 (<5 to 14) <5 (<5 to 8) 11 (<5 to 32) <0.001
ESR (mm/hr)
-cat; >24 (%) 50 33 72 <0.001
-cont; median (IQR) 24 (13 to 50) 18 (9 to 13) 45 (24 to 67) <0.001
RF; Pos (%) Neg, Pos 193, 24 97, 65 <0.001




Grey-sale synovotis ∑ semi-quant. score/16 joints:
≥2 (%)
35.1 19.4 56.2 <0.001
∑ semi-quant score/6 joints (worst hand): ≥2 (%) 29.6 15 48.8 <0.001
Number of joints/16 scoring ≥1:
≥3 (%)
30.1 14.7 50.6 <0.001
Power Doppler synovitis ∑ semi-quant. Score/16 joints:
≥1 (%)
29 15.7 46.9 <0.001
Number of joints/16 scoring ≥1:
≥2 (%)
16.9 7.4 29.6 <0.001
Baseline data for study cohort, and univariate analysis amongst patients with persistent inflammatory versus non-inflammatory diagnostic outcomes. Clinical and
laboratory parameters are considered in both continuous (cont.) and categorical (cat.) formats. ACPA, anti-citrullinated peptide antibody; EMS, early morning
stiffness; IQR, inter-quartile range; JPS, joint pattern score; RF, rheumatoid factor; SD, standard deviation, SxDur, symptom duration; T/SJC, tender/swollen joint
count, (see Methods for derivation). Baseline MSUS data and corresponding univariate analysis (employing predetermined, optimal cut-off values for each
dichotomous parameter) is also presented. ∑, sum of, semi-quant, semi-quantitative; PIA, persistent inflammatory arthritis. *Mann-Whitney U/Student’s t tests for
skewed/normally-distributed continuous data respectively; Pearson’s c2 with Yates’ continuity correction for dichotomous data.
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replaced by the MSUS parameter, “ ≥3/16 specified
joints with any grey-scale synovitis”. This model was
again significantly associated with outcome (c2 (7
degrees of freedom) = 255.8; P < 0.001), explaining
between 49% (Cox and Snell R square) and 66% (Nar-
gelkerke R squared) of the variance in diagnostic out-
come [23]. The simplified risk metric for clinical use
was then revised to incorporate the new MSUS para-
meter in place of joint pattern score (Figure 3). Based
on the ROC curves constructed from metrics that did
or did not include MSUS parameter(s), the diagnostic
utility of the new metric (which required MSUS) was
seen to be equivalent to, but not superior to, that
derived from more readily obtainable clinical and serolo-
gical parameters alone (area under both curves 0.91;
SEM 0.015; P < 0.001) (Figure 2).
A predictive algorithm for RA amongst the PIA sub-
cohort is not improved by the incorporation of MSUS
parameter(s)
Using the principals applied to the early arthritis cohort
as a whole, described above, simplified risk metrics were
developed to discriminate between PIA patients diag-
nosed with RA versus alternate inflammatory arthritides,
exploring the value added for such purposes by the
incorporation of MSUS. Hence, excluding MSUS para-
meters, backward stepwise regression identified five
Table 4 Predicting PIA in EAC patients: results of
backward stepwise regression, excluding MSUS variables
Variable Coding if
categorical
B SE Wald P-value OR
(95% CI)
Age (years) <50: 0




n/a -0.030 0.01 12.64 <0.001 0.97
(0.96 to 0.99)
SJC /72 <1: 0
≥1: 1 1.53 0.31 23.94 <0.001 4.61
(2.50 to 8.43)
JPS n/a 0.42 0.26 2.66 0.100 1.52
(0.92 to 2.52)
CRP (g/l) <5: 0
5 to 14: 1 0.77 0.21 13.48 <0.001 2.16
(1.43 to 3.27)
≥14: 2
ESR (mm/h) <24 0
≥24 1 0.79 0.34 5.33 0.021 2.21
(1.13 to 4.32)
ACPA Neg: 0
Pos: 1 4.89 1.10 21.36 <0.001 132.4
(17 to 1052)
Constant -2.12 0.52 16.63 <0.001 -
Results of backward stepwise logistic regression analysis to identify
independent clinical (non-MSUS) predictors of PIA amongst EA clinic
attendees. B values are regression coefficients. CI, confidence interval; OR,
odds ratio; SE, standard error of B. Additional abbreviations as per Table 3.
See text.
Figure 1 Risk metric calculation tool (MSUS not required). Risk
metric calculation tool for use in clinical practice, in which MSUS is
not required.
Figure 2 ROC curve comparing discriminatory utility of
predictive metrics for persistent inflammatory arthritis. Receiver
operator characteristic (ROC) curve illustrating the discriminatory
utility of two risk metrics, derived excluding or incorporating
musculoskeletal ultrasound (MSUS) parameters, with respect to an
outcome of PIA ("No MSUS” and “MSUS” respectively; area under
both curves 0.91; SEM 0.015; P < 0.001).
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variables independently associated with an outcome of
RA in this sub-cohort (n = 162); namely age, swollen
joint count, joint pattern score, ESR and ACPA status
(Table 6). By additionally entering five discriminatory
MSUS parameters into the regression analysis a similar
predictive model was derived, comprising five indepen-
dent variables, which differed only in that a dichoto-
mous power Doppler semi-quantitative score (total ≥1
for total of 16 scanned joints) replaced swollen joint
count (SJC) ≥1 (Table 7). However, the respective discri-
minatory ability of simplified risk metrics derived from
the two predictive models were comparable, suggesting
that MSUS did not add value to clinical and serological
parameters alone in identifying PIA patients who
develop RA (Figure 4). Further additive roles for MSUS
in predicting clinically relevant outcomes in early arthr-
tis patients were explored. For example, using similar
approaches, we were unable to demostrate its enhanced
ability to predict PIA in a sub-cohort of EA clinic atten-
dees who present without clinical evidence of swollen/
inflamed joints, or to predict progression to RA amongst
those individuals who present with UA (n = 204 and
n = 91, respectively; data not shown).
Table 5 Predicting PIA in eac patients: results of backward stepwise regression, incorporating MSUS variables
Variable Coding if categorical B SE Wald P-value OR (95% CI)
Age (years) <50: 0
≥50: 1 -1.24 0.36 11.81 0.001 0.29 (0.14 to 0.59)
Sx Durn
(weeks)
n/a -0.03 0.01 11.182 0.001 0.97 (0.96 to 0.99)
SJC /72 <1: 0
≥1: 1 1.42 0.32 19.21 <0.001 4.14 (2.19 to 7.80)
CRP (g/l) <5: 0
5 to 14: 1 0.64 0.22 8.43 0.004 1.89 (1.23 to 2.92)
≥14: 2
ACPA Neg: 0
Pos: 1 4.97 1.07 21.74 <0.001 143.7(18 to 1060)
ESR (mm/h) 24: 0
≥24: 1 1.00 0.36 7.74 0.005 2.72 (1.34 to 5.51)
Presence of Grade I grey-scale synovitis in ≥3/16 joints No: 0
Yes: 1 1.6 0.34 17.22 <0.001 4.91 (2.32 to 10.4)
Constant -1.62 0.34 22.68 <0.001 -
Results of logistic regression analysis of 5 MSUS paramteres in addition to 7 previously identified independent predictors for PIA amongst 379 patients of EAC
cohort. B values are regression coefficients. CI, confidence interval; OR, odds ratio; SE, standard error of B. Additional abbreviations as per Table 3. See text.
Figure 3 Risk metric calculation tool (includes MSUS parameter).
Revised risk metric calculation tool for use in clinical practice,
derived from baseline variables that included musculoskeletal
ultrasound (MSUS) parameters; an assessment of grey-scale synovitis
is a required component of the resultant risk metric.
Table 6 Predicting RA in PIA patients: results of
backward stepwise regression, excluding MSUS variables
Variable Coding if
categorical
B SE Wald P-value OR (95% CI)
Age (years) <50: 0
≥50: 1 1.52 0.49 9.52 0.002 4.58
(1.74 to 12)
SJC /72 <1: 0
≥1: 1 1.26 0.55 5.21 0.023 3.52
(1.19 to 10)
JPS n/a 1.38 0.50 7.67 0.006 3.99
(1.50 to 11)
ESR (mm/h) <24 0
≥24 1 1.14 0.53 4.63 0.031 3.13
(1.11 to 8.85)
ACPA Neg: 0
Pos: 1 4.30 0.88 24.17 <0.001 74
(13 to 409)
Constant -5.61 1.26 20.0 <0.001 -
Results of backward stepwise logistic regression analysis to identify
independent clinical (non-MSUS) predictors of RA amongst PIA sub-cohort. B
values are regression coefficients. CI, confidence interval; OR, odds ratio; SE,
standard error of B. Additional abbreviations as per Table 3. See text.
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Discussion
We present a predictive algorithm, developed in a “true-
to-life” EA clinic setting in the UK (Figure 1), which
may be used to estimate the probability that an indivi-
dual EA clinic attendee will develop a PIA. Predicting
persistent inflammatory disease amongst EA clinic
attendees, rather than mere fulfilment of classification
criteria for RA (based on the 1987 ACR classification
criteria for the disease), sets our study’s objectives apart
from those of van der Helm-van Mil et al. [7,16], but
our approach bears similarities with those of others. In
the well-known example of Visser et al., an 8-point
scoring system for use amongst EA patients was devel-
oped (maximum score 13) that permitted the probabli-
lity of PIA to be calculated for an individual patient
[11]. Unsurprisingly, the component parameters identi-
fied in that analysis overlapped with those of the current
study (Figure 1), particularly emphasising the predictive
importance of symptom duration, distribution of
involved joints and ACPA status for PIA. Unlike the
cohort studied by Visser et al., however, it is important
to note that ours included some patients with no objec-
tively swollen joints at baseline; this was in order to cap-
ture the clinically important “inflammatory arthralgia”
group. This probably explains the inclusion of swollen
joint count and CRP parameters in our own (but not in
Visser et al.’s) predictive model.
Our study addressed a highly relevant clinical ques-
tion: whether MSUS, considered alongside more readily
obtainable clinical and laboratory measurements, helps
to predict PIA amongst unselected EAC patients
referred from primary care with recent-onset joint pain.
The comprehensiveness of any MSUS screening proto-
col used for this purpose needs to be balanced by the
feasibility of its use as part of a time-constrained, rou-
tine clinical assessment, and we developed a protocol
that could in most cases be completed within 10 min-
utes, focussing on small peripheral joints. In our hands,
MSUS parameters provided no additional discriminatory
value under these circumstances (Figure 2). The inde-
pendent contribution of ACPA status to predictive mod-
els for PIA was remarkable, being reflected in the
magnitude of its associated regression coefficient (4.89;
Table 4), implying that the adoption of autoantibody
testing as a diagnostic tool in this setting provides
superior discriminatory utility over the MSUS screening
Table 7 Predicting RA in PIA patients: results of backward stepwise regression, incorporating MSUS variables
Variable Coding if categorical B SE Wald P-value OR (95% CI)
Age (years) <50: 0
≥50: 1 1.26 0.51 6.23 0.013 3.59 (1.32 to 9.81)
Presence of GradeIPower Doppler synovitis in ≥1/16 joints No: 0
Yes: 1 1.70 0.52 10.72 0.001 5.46 (1.98 to 15.1)
JPS n/a 1.39 0.54 6.60 0.010 4.02(1.39 to 11.6)
ESR (mm/h) 24: 0
≥24: 1 1.17 0.56 4.48 0.034 3.24 (1.09 to 9.60)
ACPA Neg: 0
Pos: 1 4.06 0.82 24.74 <0.001 58.1(12 to 288)
Constant -5.38 1.28 17.64 <0.001 -
Results of logistic regression analysis of maximally discriminatory MSUS paramters in addition to previously identified independent predictors for UA amongst
162 patients of PIA sub-cohort. B values are regression coefficients. CI, confidence interval; OR, odds ratio; SE, standard error of B. Additional abbreviations as per
Table 3. See text.
Figure 4 ROC curve comparing discriminatory utility of
predictive metrics for RA amongst PIA sub-cohort. Receiver
operator characteristic (ROC) curve illustrating the discriminatory
utility of two risk metrics derived amongst the PIA sub-cohort alone,
excluding or incorporating musculoskeletal ultrasound (MSUS)
parameters, with respect to an outcome of rheumatoid arthritis (RA)
("No MSUS” and “MSUS” respectively). Area under curves: 0.93 (No
MSUS; SEM 0.021; P < 0.001), 0.89 (MSUS; SEM 0.025; P < 001).
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parameters presented here. With 57% of EAC patients
having non-inflammatory outcomes, it may be argued
that the discriminatory utility of MSUS would be better
defined when discriminating patients with an outcome
of classifiable RA amongst the sub-cohort with PIA, but
this was not found to be the case in our study (Figure
4). Neither were we able to demonstrate an additive pre-
dictive utility of MSUS when predicting progression of
(i) arthralgia (in the absence of clinically evident synovi-
tis) to PIA, or (ii) UA to RA - although our study lacked
power to exclude either of these comprehensively. It is
nonetheless noteworthy that the backward selection pro-
cedure employed during regression analyses suggested
that the independent association amongst PIA patients
of RA outcome with the presence of one or more clini-
cally swollen joints was less strong than it was with the
presence of any power Doppler signal in the 16 screened
peripheral joints (compare respective odds ratios, Tables
6 and 7). The quantitative lack of additive discrimina-
tion provided by MSUS in these settings does not,
therefore, negate the value of this imaging modality as
an extension of the clinical examination in the evalua-
tion of early arthritis.
Our observational study has a number of limitations,
primarily reflecting the opportunistic manner in which
data were collected in a real-time, real-life and busy EA
clinic. Data published by others during the course of
our study have suggested that the wrists and (albeit in
the longitudinal evaluation of established disease) the
fifth MTPJs may have particular value as sensitive mar-
kers of inflammatory arthritis [13,25], but these joints
were not included in our routine screening algorithm.
Conversely the first MTPJ frequently contains an effu-
sion of equivocal significance and is the least informa-
tive MTPJ [13]. Although we discounted a semi-
quantitative greyscale score of 1 at this site (see Meth-
ods), our inclusion of the first MTPJ may, therefore,
have influenced our findings, and our routine screening
protocol might have yielded superior discriminatory
value had it been informed by the detailed pilot work of
Filer et al. [13]. Further work is required to define an
optimal short MSUS screening protocol for use in the
early arthritis setting, and, in particular, the extent to
which it should include extra-articular sites, for exam-
ple, to determine the presence of tenosynovitis or enthe-
sitis. Finally, the definition of PIA was pragmatic, being
based upon outcome diagnoses at follow-up, and the
classification of each diagnosis for this purpose was not
intuitive in all cases. For example, it was decided to
define patients with crystal arthropathy (gout and cal-
cium pyrophosphate deposition) as non-PIA, since such
patients are not considered candidates for DMARDs,
and their appropriate management in this cohort
ensured that inflammatory manifestations were, for the
most part, self-limiting. Their number was relatively
small (n = 17), and classifying them alternatively as PIA
did not materially alter the overall outcome of the
analysis.
Notwithstanding the above, we set out to address
whether MSUS parameters added to more readily
obtainable clinical and laboratory data in the generation
of predictive models in the EAC. In this regard, our
large EAC cohort adds a substantial dataset to inform
current knowledge and debate.
Conclusions
A “risk metric” using baseline clinical parameters pre-
dicts early arthritis patients who develop PIA. The
incorporation of MSUS parameters does not add discri-
minatory value to the risk metric. Further studies will
determine the role of MSUS in the diagnosis of early
arthritis.
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